The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy-Reference-Cited by-同舟云学术

The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy

Published:2020-08 Issue:4 Volume:18 Page:252-257.e2
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Hamieh Lana,Beck Rachel L.,Le Valerie H.,Hsieh James J.

Funder

Novartis

Eisai

National Institutes of Health

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference23 articles.

1. Renal cell carcinoma;Hsieh;Nat Rev Dis Primers,2017

2. NCCN Guidelines updates: management of metastatic kidney cancer;Jonasch;J Natl Compr Canc Netw,2019

3. A river model to map convergent cancer evolution and guide therapy in RCC;Wei;Nat Rev Urol,2015

4. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2019

5. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy;Heng;Ann Oncol,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effectiveness of the combination of lenvatinib and everolimus in metastatic renal cell carcinoma in patients with resistance to targeted treatment in real clinical practice;Medical alphabet;2024-05-09

2. Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients;Therapeutic Advances in Urology;2024-01

3. Impact of primary resistance to front-line targeted therapy in metastatic renal cell carcinoma on subsequent immune-checkpoint-inhibition;Discover Oncology;2023-09-23

4. Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity;Exploration of Targeted Anti-tumor Therapy;2023-08-31

5. Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma;Frontiers in Oncology;2023-07-27